Although no significant changes in the proportion of CD74+ SMCs were found in this study, we suggest that the proportion changes of CD74+ SMCs and CCL19+ fibroblasts in patients may reflect the progression of JDM. This evidence concerns the gene CCL19 and juvenile dermatomyositis.